A San Diego biotech is working on therapies that could tackle life-altering conditions, like autoimmune diseases and cancer, by modifying cells. But instead of engineering cells in a lab, they're doing it inside your body. Thanks to that novel approach and the support of some of the biggest names in the pharmaceutical industry, Capstan Therapeutics has netted $175 million in a fundraising round, despite a sluggish venture capital environment for startups.
“This is why our industry needs to have a different approach so that we can bring it forward to more people in an easier way.” Capstan encodes mRNA and packages it in a lipid nanoparticle that is “decorated” with an antibody, which directs the body’s T-cells to attack problematic cells. There are broad applications for this platform technology, Shawver said, but right now Capstan is looking at ways to treat cancer, fibrosis, and autoimmune and genetic blood disorders.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk and Eli Lilly rival soars 35% after promising weight loss drug resultsZealand Pharma's Phase 2 trial was an 'uniquivocal win' for a drug that can treat both liver disease and obesity, analysts said.
Source: CNBC - 🏆 12. / 72 Read more »
Eli Lilly's Alzheimer's drug delayed by FDA: ‘It was unexpected’On Friday, the FDA announced it would postpone a decision on Eli Lilly's potential Alzheimer's treatment donanemab.
Source: FOX10Phoenix - 🏆 83. / 68 Read more »
Eli Lilly's new ad says weight-loss drugs shouldn't be used out of 'vanity'In a new ad that nods to the 2024 Oscars, the pharmaceutical firm discourages people from using drugs like Mounjaro for cosmetic weight loss.
Source: CBSNews - 🏆 87. / 68 Read more »
Eli Lilly says Alzheimer’s drug approval delayed as FDA seeks input from advisersDrugmaker Eli Lilly says that approval of its experimental Alzheimer’s medication donanemab will be delayed beyond the end of March as the FDA plans to call a last-minute meeting of its advisers
Source: wrtv - 🏆 598. / 51 Read more »
Stocks making the biggest moves midday: Nvidia, Marvell Technology, Costco, Eli Lilly and moreThese are the stocks posting the largest moves in midday trading.
Source: CNBC - 🏆 12. / 72 Read more »
Eli Lilly's campaign seeks to resolve weight-loss drug misconceptionsEli Lilly is launching a campaign aimed at informing consumers about the seriousness of diabetes as a disease and the appropriate use of its weight-loss-related drugs.
Source: FoxBusiness - 🏆 458. / 53 Read more »